OR WAIT null SECS
© 2021 MJH Life Sciences and BioPharm International. All rights reserved.
© 2021 MJH Life Sciences™ and BioPharm International. All rights reserved.
Cell-free expression shows promise in preclinical applications but presents scale-up challenges.
Demand for recombinant microorganism-based cell culture supplements.
April 02, 2021
Biopharmaceutical companies and contract manufacturers respond to changing demand dynamics for upstream bioprocessing capacity.
The innovation of single-use technologies is applicable early on in the manufacturing process.
March 02, 2021
Overcoming time and cost constraints can help enable seed train intensification efforts to maximize product yield.
February 02, 2021
Connected, integrated bioprocessing enterprises with greater data analytics capabilities are coming.
January 02, 2021
Cell-culture optimization may see benefits from a synthetic biology-based approach that improves product titer, quality, and time.
December 02, 2020
Establishing an automated inline dilution system can potentially ease bottlenecking delays resulting from higher upstream yields.
November 02, 2020
PAT advances are enabling improved process understanding, process control, and error prevention.
October 02, 2020
An innovation such as synthetic biology can develop a consistently stable starting cell line for cell therapy source material.
Bioreactor technology advances can offer seamless manufacturing scale-up and can reduce the timeline and cost of biologics production.
September 03, 2020
This article will explore the traditional path from the laboratory to the clinic and how the fixed-bed technology provides an alternative solution to meet commercial demands.